JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2004; 43:1929-1939, doi:10.1016/j.jacc.2004.01.035
© 2004 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diamond, G. A.
Right arrow Articles by Kaul, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diamond, G. A.
Right arrow Articles by Kaul, S.

STATE-OF-THE-ART PAPER

Prior convictions

bayesian approaches to the analysis and interpretation of clinical megatrials

George A. Diamond, MD, FACC*,* and Sanjay Kaul, MD*

* Division of Cardiology, Cedars-Sinai Medical Center, and the School of Medicine, University of California, Los Angeles, California, USA

Manuscript received October 1, 2003; revised manuscript received January 2, 2004, accepted January 12, 2004.

* Reprint requests and correspondence: Dr. George A. Diamond, 2408 Wild Oak Drive, Los Angeles, California 90068, USA.
gadiamond{at}pol.net

Large, randomized clinical trials ("megatrials") are key drivers of modern cardiovascular practice, since they are cited frequently as the authoritative foundation for evidence-based management policies. Nevertheless, fundamental limitations in the conventional approach to statistical hypothesis testing undermine the scientific basis of the conclusions drawn from these trials. This review describes the conventional approach to statistical inference, highlights its limitations, and proposes an alternative approach based on Bayes’ theorem. Despite its inherent subjectivity, the Bayesian approach possesses a number of practical advantages over the conventional approach: 1) it allows the explicit integration of previous knowledge with new empirical data; 2) it avoids the inevitable misinterpretations of p values derived from megatrial populations; and 3) it replaces the misleading p value with a summary statistic having a natural, clinically relevant interpretation—the probability that the study hypothesis is true given the observations. This posterior probability thereby quantifies the likelihood of various magnitudes of therapeutic benefit rather than the single null magnitude to which the p value refers, and it lends itself to graphical sensitivity analyses with respect to its underlying assumptions. Accordingly, the Bayesian approach should be employed more widely in the design, analysis, and interpretation of clinical megatrials.

Abbreviations and Acronyms
  CI = confidence interval
  FRISC = Fragmin and Fast Revascularization during InStability in Coronary artery disease trial
  HPS = Heart Protection Study
  LIFE = Losartan Intervention for Endpoint reduction in hypertension trial
  OR = odds ratio
  PURSUIT = Platelet Glycoprotein IIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin Therapy trial
  RITA = Randomized Intervention Treatment of Angina trial
  TACTICS TIMI-18 = Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction-18 trial
  TIMI-IIIB = Thrombolysis In Myocardial Infarction-IIIB trial
  VANQWISH = Veterans Affairs Non–Q-wave Infarction Strategies in Hospital trial




This article has been cited by other articles:


Home page
J Clin PharmacolHome page
B. Ameer
Novel Trial Design: A Report From the 19th Frontiers Symposium of ACCP
J. Clin. Pharmacol., July 1, 2008; 48(7): 793 - 798.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
N. K J Adhikari and D. C Scales
Corticosteroids for acute respiratory distress syndrome
BMJ, May 3, 2008; 336(7651): 969 - 970.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. A. Diamond and S. Kaul
COURAGE Under Fire: On the Management of Stable Coronary Disease
J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1604 - 1609.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Kaul, P. K. Shah, and G. A. Diamond
As Time Goes By: Current Status and Future Directions in the Controversy Over Stenting
J. Am. Coll. Cardiol., July 10, 2007; 50(2): 128 - 137.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
S. Eshaghian, S. Kaul, S. Amin, P. K. Shah, and G. A. Diamond
Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease
Ann Intern Med, March 20, 2007; 146(6): 434 - 441.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
F.-J. Neumann, A. Kastrati, and G. Schwarzer
New aspects in the treatment of acute coronary syndromes without ST-elevation: ICTUS and ISAR-COOL in perspective
Eur. Heart J. Suppl., February 1, 2007; 9(suppl_A): A4 - A10.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Kaul, A. A. Zadeh, and P. K. Shah
Homocysteine Hypothesis for Atherothrombotic Cardiovascular Disease: Not Validated
J. Am. Coll. Cardiol., September 5, 2006; 48(5): 914 - 923.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
S. Kaul and G. A. Diamond
Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials
Ann Intern Med, July 4, 2006; 145(1): 62 - 69.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Holzer, M. Mullner, F. Sterz, O. Robak, A. Kliegel, H. Losert, G. Sodeck, T. Uray, A. Zeiner, and A. N. Laggner
Efficacy and Safety of Endovascular Cooling After Cardiac Arrest: Cohort Study and Bayesian Approach
Stroke, July 1, 2006; 37(7): 1792 - 1797.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. S. Vasan
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Circulation, May 16, 2006; 113(19): 2335 - 2362.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Kaul, G. A. Diamond, and W. S. Weintraub
Trials and Tribulations of Non-Inferiority: The Ximelagatran Experience
J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1986 - 1995.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. G. Robinson, B. Smith, N. Maheshwari, and H. Schrott
Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?: A Meta-Regression Analysis
J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1855 - 1862.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
G. Howard, C. S. Coffey, and G. R. Cutter
Is Bayesian Analysis Ready for Use in Phase III Randomized Clinical Trials?: Beware the Sound of the Sirens
Stroke, July 1, 2005; 36(7): 1622 - 1623.
[Full Text] [PDF]


Home page
JAMAHome page
F. Buccelletti
Reviparin in Acute Myocardial Infarction
JAMA, June 1, 2005; 293(21): 2595 - 2595.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
American College of Cardiology and the American He, J. A. Spertus, K. A. Eagle, H. M. Krumholz, K. R. Mitchell, and S.-L. T. Normand
American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care
J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1147 - 1156.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. A. Spertus, K. A. Eagle, H. M. Krumholz, K. R. Mitchell, S.-L. T. Normand, and for the American College of Cardiology and the Ame
American College of Cardiology and American Heart Association Methodology for the Selection and Creation of Performance Measures for Quantifying the Quality of Cardiovascular Care
Circulation, April 5, 2005; 111(13): 1703 - 1712.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2004 by the American College of Cardiology Foundation.